Our Solution: TTC-352
TTC-352 is an orally-administered selective human estrogen receptor (ER) partial agonist (ShERPA) designed to treat metastatic ER+ breast cancers that have become resistant to endocrine therapy and CDK4/6 inhibitor therapy.
TTC-352 builds on the mechanism of action of estradiol, interacting with estrogen receptor on tumor cells leading to tumor regression, but without the magnitude of side effects.
Overview of TTC-352 Attributes
Novel mechanism of action for hormonal therapy of breast cancer
Effective in heavily-pretreated ER+ breast cancer after failure of hormonal therapy and CDK4/6 inhibitors
Biomarker predicting activity in development (PKCa overexpression)
Oral capsule delivery
Human safety established
Significant key opinion leaders support for novel, non-toxic breast cancer therapy
Clinical Trial Results
Completed phase I clinical trial confirmed that the drug is safe and demonstrated encouraging efficacy in patients with refractory ER+ breast cancer that is heavily pretreated with hormonal and chemotherapy refractory breast cancer.
In addition, a biomarker of benefit has been identified (PKCa overexpression).